Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease

Lancet

Volumn 349, Issue 9051, 1997, Pages 521-524

  Stack, W A ^a   Mann, S D ^b   Roy, A J ^b   Heath, P ^c   Sopwith, M ^c   Freeman, J ^d   Holmes, G ^d   Long, R ^a   Forbes, A ^b   Kamm, M A ^b   Hawkey, C J ^a,e  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

^c UCB PHARMA   (Belgium)

^d DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 GLYCOPROTEIN; C REACTIVE PROTEIN; HUMAN ALBUMIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLATULENCE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; VERTIGO;

EID: 0031043778     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)80083-9     Document Type: Article

References (20)

1. Breese EJ, Michie CA, Nicholls SW, et al. Tumour necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-66.
2. Braegger CP, Nicholls S, Murch SH, Stephens S, Macdonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
3. Reinecker HC, Steffert M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
4. Lukacs NW, Chensue SW, Strieter R, Warmington K, Kunkel SL. Inflammatory granuloma formation is mediated by TNF-alpha inducible intercellular adhesion molecule. J Immunol 1994; 152: 5883-89.
5. Le J, Vilcek J. Tumour necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234-48.
6. Brynskov J, Freund L, Rasmussen SN, et al. A placebo controlled double blind randomised trial of cyclosporin therapy in active Crohn's disease. N Engl J Med 1989; 321: 845-50.
7. Feagen BG, McDonald JWD, Rochon J, et al. Low dose cyclosporin for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51.
8. Stronhorst A, Tytgat GNJ, van Deventer SJH. CD4 antibody treatment in Crohn's disease. Scand J Gastroenterol 1992; 27 (suppl): 61-65.
9. Strange EF, Modigiani R, Pena AS, et al. European trial of cyclosporin in chronic active Crohn's disease - a 12 month study. Gastroenterology 1995; 109: 774-82.
10. Elliott MJ, Maini RN, Feldmann M, et al Randomised double-blind comparison of chimeric monoclonal antibody 10 tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
11. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42.
12. Rankin ECC, Choy EHS, Sopwith M, Vetterlein O, Panayi GS, Isenberg DA. Repeated doses of 10 mg/kg of an engineered human anti-TNF alpha antibody CDP571, in RA patients are safe and effective. Arthritis Rheum 1995; 38: A197 (abstr).
13. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-74.
14. Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
15. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995; 85: 668-74.
16. Best WR, Becktel JM, Singleton JW, Kern F. Development of Crohn's disease activity index. Gastroenterology 1976; 70: 439-44.
17. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; i: 514.
18. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalazine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Gastroenterology 1993; 104: 1293-301.
19. Knight DM, Trinh H, Le J, et al. Construction and initial characterisation of a mouse-human anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
20. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996; 156: 1646-53.